Kiniksa Pharmaceuticals (KNSA)

Executive Summary

Kiniksa Pharmaceuticals is a global biopharmaceutical company focused on immune-modulating therapies for cardiovascular and autoimmune diseases. The company's lead commercial product, ARCALYST (rilonacept), is approved for recurrent pericarditis and provides a steady revenue base. Kiniksa's pipeline includes KPL-387, a Phase 2 candidate for recurrent pericarditis with a novel mechanism, and KPL-404, a Phase 2 candidate for rheumatoid arthritis. The company also has early-stage programs targeting Sjögren's disease and other autoimmune conditions. With a strong commercial foundation and a pipeline addressing significant unmet needs, Kiniksa is positioned for growth, though near-term catalysts are centered on clinical data and potential label expansions.

Upcoming Catalysts (preview)

• Q4 2026KPL-387 Phase 2 interim data readout for recurrent pericarditis60% success
• TBDPotential FDA label expansion for ARCALYST in new indications40% success
• Q3 2026KPL-404 Phase 2 topline results in rheumatoid arthritis50% success